ASMB
ASSEMBLY BIOSCIENCES, INC.
NASDAQ · Healthcare · Biotechnology · US
$20.16
+0.35%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$20.22
From 52W high−47.64%
Volume199155.00
Market cap$410.47M
P/E (TTM)36.7x
P/S (TTM)5.5x
Div yield—
Key dataOct 19, 2026
Open
$20.22
From 52W high
−47.64%
Volume
199155.00
Market cap
$410.47M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
1359.7x
P/E (TTM)
36.7x
RSI (14)
25.8
MomentumView details →
1D Return
+0.35%
YTD Return
−41.22%
SummaryUpdated Jun 1, 2026
Assembly Biosciences, Inc. (NASDAQ:ASMB) is a clinical-stage biotechnology company founded in 2005 and headquartered in South San Francisco, California. Originally incorporated as Ventrus Biosciences, the company changed its name to Assembly Biosciences in June 2014. The company went public in December 2010 and focuses exclusively on developing therapeutic treatments for hepatitis B virus (HBV) infection, a serious liver disease that affects hundreds of millions of people worldwide.
Similar companies
Latest newsMore news →
Assembly Biosciences announced it will present positive Phase 1a safety, tolerability and target engagement data for ABI-6250 at AASLD The Liver Meeting 2026.15d agoAssembly Biosciences exercised its U.S. profit-share option with Gilead Sciences for its HSV helicase-primase inhibitor program, agreeing to share 40% of U.S. development costs and profits.42d ago